Target intelligence / Profile preview

Airway epithelial cells and respiratory tract mucus

Molecular classification
Other (Tissue/Biological Barrier)
01

Overview

The airway epithelial cells and the respiratory tract mucus layer form the integrated "mucociliary escalator," which serves as the primary physical and immunological defense against inhaled pathogens and particulates [1]. The epithelium is a pseudostratified layer containing ciliated cells, which provide the motive force for clearance, and goblet cells, which secrete the gel-forming mucins MUC5AC and MUC5B [2]. These mucins create a viscoelastic hydrogel that traps debris, while the underlying airway surface liquid (ASL) provides the necessary environment for ciliary activity [3]. In chronic respiratory diseases such as cystic fibrosis and COPD, mucus becomes hyperviscous or overproduced, leading to airway obstruction, inflammation, and a niche for bacterial growth [1,4]. Therapeutic strategies targeting this system include mucolytics that break down the mucus structure and ion channel modulators that aim to rehydrate the ASL to restore effective clearance [1,2]. References: [1] Fahy JV, Dickey BF. N Engl J Med. 2010;363(23):2233-47. [2] Whitsett JA. Ann Am Thorac Soc. 2018;15(Suppl 3):S143-S148. [3] Bustamante-Marin XM, Ostrowski LE. Cold Spring Harb Perspect Biol. 2017;9(4):a028241. [4] Rogers DF. Respir Care. 2007;52(9):1134-46.

Other names
Respiratory epitheliumAirway surface liquidTracheobronchial mucusBronchial epitheliumMucociliary escalator
02

Mechanism of action

Reduction of disulfide bonds in mucin polymers (mucolysis); enzymatic cleavage of extracellular DNA; modulation of CFTR-mediated chloride transport to increase hydration; suppression of inflammatory cytokine production in epithelial cells.

03

Biological functions

Barrier functionMucociliary clearanceInnate immunityFluid and electrolyte transportPathogen trapping
04

Disease associations

Cystic fibrosisChronic obstructive pulmonary disease (COPD)AsthmaBronchitisRespiratory tract infection
05

Safety considerations

Risk of bronchospasm with inhaled mucolyticsPotential for mucosal irritationDisruption of protective barrier leading to secondary infectionCiliary dyskinesia
06

Interacting drugs

N-acetylcysteine

5 more in the full profile.

07

Biomarkers

MUC5AC protein levelsMUC5B protein levelsSputum eosinophil countCiliary beat frequencyAirway surface liquid height

Beyond the preview

Go deeper on Airway epithelial cells and respiratory tract mucus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Airway epithelial cells and respiratory tract mucus.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call